ADMA Biologics, Inc. (NASDAQ:ADMA) Shares Sold by Two Sigma Advisers LP

Two Sigma Advisers LP lessened its position in shares of ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) by 4.3% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 4,454,400 shares of the biotechnology company's stock after selling 200,200 shares during the quarter. Two Sigma Advisers LP owned about 1.91% of ADMA Biologics worth $89,043,000 as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. Healthcare of Ontario Pension Plan Trust Fund grew its stake in ADMA Biologics by 13.9% during the 3rd quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 658,900 shares of the biotechnology company's stock worth $13,171,000 after buying an additional 80,400 shares during the last quarter. Assenagon Asset Management S.A. grew its stake in shares of ADMA Biologics by 2.7% in the 3rd quarter. Assenagon Asset Management S.A. now owns 3,474,455 shares of the biotechnology company's stock valued at $69,454,000 after purchasing an additional 92,281 shares during the last quarter. Citigroup Inc. grew its stake in shares of ADMA Biologics by 251.7% in the 3rd quarter. Citigroup Inc. now owns 387,226 shares of the biotechnology company's stock valued at $7,741,000 after purchasing an additional 277,138 shares during the last quarter. Seven Eight Capital LP purchased a new position in shares of ADMA Biologics in the 2nd quarter valued at approximately $1,992,000. Finally, Principal Financial Group Inc. grew its stake in shares of ADMA Biologics by 785.7% in the 3rd quarter. Principal Financial Group Inc. now owns 1,194,221 shares of the biotechnology company's stock valued at $23,872,000 after purchasing an additional 1,059,394 shares during the last quarter. Hedge funds and other institutional investors own 75.68% of the company's stock.

Insider Buying and Selling

In other news, CFO Brad L. Tade sold 15,000 shares of the business's stock in a transaction on Friday, November 22nd. The stock was sold at an average price of $21.15, for a total value of $317,250.00. Following the completion of the transaction, the chief financial officer now directly owns 199,433 shares of the company's stock, valued at $4,218,007.95. The trade was a 7.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Lawrence P. Guiheen sold 9,000 shares of the business's stock in a transaction on Monday, September 9th. The stock was sold at an average price of $18.47, for a total value of $166,230.00. Following the completion of the transaction, the director now directly owns 153,941 shares of the company's stock, valued at approximately $2,843,290.27. This trade represents a 5.52 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 3.70% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on ADMA shares. Cantor Fitzgerald reiterated an "overweight" rating and issued a $20.00 target price on shares of ADMA Biologics in a research note on Friday, September 20th. Raymond James lifted their price target on ADMA Biologics from $18.00 to $25.00 and gave the company a "strong-buy" rating in a research note on Friday, November 8th. Finally, HC Wainwright lifted their price target on ADMA Biologics from $18.00 to $26.00 and gave the company a "buy" rating in a research note on Friday, November 8th.

ADMA Biologics Price Performance

Shares of ADMA Biologics stock traded up $0.45 during trading on Friday, reaching $19.77. The company's stock had a trading volume of 1,340,329 shares, compared to its average volume of 3,604,288. The company has a quick ratio of 3.26, a current ratio of 7.09 and a debt-to-equity ratio of 0.48. ADMA Biologics, Inc. has a 12-month low of $3.60 and a 12-month high of $23.64. The company has a market capitalization of $4.67 billion, a P/E ratio of 69.00 and a beta of 0.70. The business has a 50 day moving average price of $19.09 and a 200-day moving average price of $15.60.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last issued its quarterly earnings data on Thursday, November 7th. The biotechnology company reported $0.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.13 by $0.02. The firm had revenue of $119.84 million during the quarter, compared to analysts' expectations of $107.25 million. ADMA Biologics had a return on equity of 53.20% and a net margin of 17.80%. During the same period in the previous year, the firm posted $0.01 earnings per share. As a group, sell-side analysts anticipate that ADMA Biologics, Inc. will post 0.52 EPS for the current year.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.